Dicerna aims to treat diseases that have never been treated before. Dicerna CEO, Dr. Douglas Fambrough, explains this is an emerging class of biotech and his company's technology is superior to its peers because the company has used an optimized form of technology to silence individual genes called RNA interference, allowing DRNA to do things the pharmaceutical industry has not been able to do before. Dr. Fambrough says investors should look at DRNA now because the company is on the verge of getting that proof of concept in patients which should, if it is successful, rapidly lead towards the FDA approval process. Over the next year, or so, DRNA will see multiple clinical programs to demonstrate patient benefit, if the drugs are successful.
Stocks in this video: